Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze CRNX Crinetics Pharmaceuticals, Inc.. Please read: https://finlab.finance/en/setup?stock=CRNX

Open Studio

CRNX

Crinetics Pharmaceuticals, Inc. Healthcare As of 2026-08-28 Updated daily after market close

quality needs a look, discounted valuation.

3 active signals
52-week adjusted-price high Top-quintile 6-month momentum Filed revenue acceleration
Valuation 44Quality 9Growth 86Momentum 98Risk / liquidity 47

Is Crinetics Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 3th percentile. TTM ROE is about -38.8%.

  • Valuation is cheaper than most peers. TTM P/E is in the 13th percentile, lower than most liquid US common stocks.

  • Recent volatility is elevated. 60-day annualized volatility is in the 98th percentile. Average 20-day dollar volume is about $185.3M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Crinetics Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

15 historical occurrences (since 2021-08-13)
Average forward return after 52-week adjusted-price high。20-day: Win 50%, Sample 14, Median +0.01%, Excess -4.02%, Beat mkt rate 42.9%；60-day: Win 46.2%, Sample 13, Median -3.44%, Excess -5.45%, Beat mkt rate 38.5%；120-day: Win 53.8%, Sample 13, Median +10.55%, Excess -0.04%, Beat mkt rate 46.2%

120 days after: historical avg +4.7%

20-day -3.58%
60-day -2.74%
120-day +4.7%
20-day
60-day
120-day
Win
50%
46.2%
53.8%
Sample
14
13
13
Median
+0.01%
-3.44%
+10.55%
Excess
-4.02%
-5.45%
-0.04%
Beat mkt rate
42.9%
38.5%
46.2%

Over 13 occurrences, 120-day forward avg gained 4.7%, lagged the market by 0.04 pts; win rate 53.8%.

Top-quintile 6-month momentum

Active · now 96.52542372881356%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

21 historical occurrences (since 2020-02-04)
Average forward return after Top-quintile 6-month momentum。20-day: Win 57.1%, Sample 21, Median +1.26%, Excess +2.58%, Beat mkt rate 47.6%；60-day: Win 55%, Sample 20, Median +1.86%, Excess -1.99%, Beat mkt rate 40%；120-day: Win 50%, Sample 20, Median +3.02%, Excess +3.51%, Beat mkt rate 45%

120 days after: historical avg +9.61%

20-day +4.43%
60-day +2.68%
120-day +9.61%
20-day
60-day
120-day
Win
57.1%
55%
50%
Sample
21
20
20
Median
+1.26%
+1.86%
+3.02%
Excess
+2.58%
-1.99%
+3.51%
Beat mkt rate
47.6%
40%
45%

Over 20 occurrences, 120-day forward avg gained 9.61%, beat the market by 3.51 pts; win rate 50%.

Filed revenue acceleration

Active · now 2277.5%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

3 historical occurrences (since 2025-11-06)

Market-wide momentum baseline

Across 97,367 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.31%, a 58.2% positive-return rate, and +2.95 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.